Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D06KSV
|
||||
Former ID |
DIB000328
|
||||
Drug Name |
Omigapil
|
||||
Synonyms |
Omigapil); CGP-3466; CGP-3499B; Neuroprotectant, Novartis; Neuroprotectant, Santhera; Nootropic agent, Novartis; Nootropicagent, Santhera; SNT-317; TCH-346; TCH-346B
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Lateral sclerosis [ICD10:G12.2] | Phase 2 | [522278] | ||
Company |
Novartis AG
|
||||
Structure |
Download2D MOL |
||||
Formula |
C19H17NO
|
||||
Canonical SMILES |
C1(=Cc2c(Oc3c1cccc3)cccc2)CN(CC#C)C
|
||||
CAS Number |
CAS 181296-84-4
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Glyceraldehyde 3-phosphate dehydrogenase, muscle | Target Info | Modulator | [528054] | |
PANTHER Pathway | Glycolysis | ||||
Huntington disease | |||||
Pathway Interaction Database | Validated targets of C-MYC transcriptional activation | ||||
Reactome | Glycolysis | ||||
Gluconeogenesis | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.